Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Follow-up of the NeoSphere study

Compelling data on the neoadjuvant use of pertuzumab

    • Congress Reports
    • Gynecology
    • News
    • Oncology
    • RX
    • Studies
  • 2 minute read

NeoSphere is a phase II trial in which 417 women with newly diagnosed HER2-positive, operable, locally advanced or inflammatory early breast cancer were randomized to four different neoadjuvant therapy arms. Surgery was followed by a one-year adjuvant therapy phase. Data from the 2015 ASCO Congress now confirm the long-term benefit of adding pertuzumab to docetaxel and trastuzumab.

The addition of pertuzumab to docetaxel and trastuzumab results in significantly more complete breast remissions (16.8% increase, p=0.0141). This is shown by data from NeoSphere, which was already published in 2012 [1]. This parameter is defined as the complete absence of detectable tumor tissue in the breast at the time of surgery. Complete remissions in breast and axilla also increased by 17.8% with the addition (39.3% vs. 21.5%, p=0.0063). Side effects did not occur more frequently.

Three-year survival data from the study have now been presented at the 2015 ASCO Congress:

  • Three years after surgery, 92% of patients who received pertuzumab, trastuzumab, and docetaxel were alive without progression, compared with 85% in the other group (trastuzumab and docetaxel). This corresponds to a risk reduction in disease-free survival of 40%.
  • Three years after randomization, 90% of the first group lived progression-free, and 86% of the second group (risk reduction in progression-free survival of 31%).
  • In the remaining two arms studied (pertuzumab and trastuzumab; pertuzumab and docetaxel), the rates for disease-free survival were 88% and 84%, and for progression-free survival were 81% and 82%.
  • The risk of progression or death was significantly reduced in those patients who achieved complete remission. Compared with study participants who missed the primary endpoint, the hazard ratio in disease-free survival here was 0.68 (95% CI 0.36-1.26) and in progression-free survival 0.54 (95% CI 0.29-1.00). This supports the notion that improvements in long-term outcome are associated with the achievement of complete remission.

Conclusion of the follow-up

Overall, the long-term data suggest a benefit of adding pertuzumab to docetaxel and trastuzumab in the neoadjuvant therapy setting (administered four cycles over 12 weeks). This not only allows significantly more women to achieve complete remission, but also extends the time without progression or  to death. This was with no change in adjuvant therapy, which in NeoSphere consisted of chemotherapy and trastuzumab in all four groups.

Based in part on the compelling data from NeoSphere, the EMA approved pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early breast cancer at high risk of recurrence at the end of July 2015.

Source: ASCO Congress, May 29-June 2, 2015, Chicago.

Literature:

  1. Gianni L, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012 Jan; 13(1): 25-32.

InFo ONCOLOGY & HEMATOLOGY 2015; 3(9-10): 3.

Autoren
  • Andreas Grossmann
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • ASCO
  • Breast Cancer
  • Docetaxel
  • NeoSphere
  • Pertuzumab
  • Trastuzumab
Previous Article
  • Follow-up after renal cell carcinoma surgery

How long is long enough?

  • Nephrology
  • News
  • Oncology
  • RX
View Post
Next Article
  • Pruritus

New developments and treatment methods against itching

  • Dermatology and venereology
  • Education
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 5 min
  • Diabetic cardiomyopathy

Echocardiography is an important tool for early detection of LVD

    • Cardiology
    • Education
    • Endocrinology and Diabetology
    • RX
    • Studies
View Post
  • 6 min
  • Hair loss

Controversy over the benefits of biotin supplementation: what is evidence-based?

    • Dermatology and venereology
    • Education
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 5 min
  • New findings on known forms of therapy

Fatigue syndrome as a leading symptom in multiple sclerosis

    • Education
    • Neurology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 5 min
  • Asthma in adults

When do pneumology specialists come into play?

    • RX
View Post
  • 10 min
  • Cutaneous lupus erythematosus

From diagnostic workup to successful treatment

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.